Efficacy News and Research

RSS

Artificial heart can keep patients awaiting heart transplant alive

The results of the nine-year study of the CardioWest Total Artificial Heart have concluded that the device prevents death in critically ill patients suffering from irreversible failure of both sides of the heart who are candidates for heart transplantation.

26 Aug 2004

Powerful new cancer-fighting property of Herceptin

For many patients with advanced breast cancer, the cancer drug Herceptin (trastuzumab) has offered new hope when traditional cancer drugs failed to work, shrinking tumors and sending some patients into remission.

23 Aug 2004

Pfizer receives approval for acute bipolar mania drug

Pfizer has announced that the U.S. Food and Drug Administration (FDA) has approved the use of its atypical antipsychotic Geodon(R) (ziprasidone HCI) for the treatment of acute bipolar mania including manic and mixed episodes.

23 Aug 2004

New database about a group of genes associated with multidrug resistance in cancerous tumors

Scientists at the National Cancer Institute, have created a database of information about a group of genes associated with multidrug resistance in cancerous tumors.

23 Aug 2004

Pfizer drug effectively treats overactive bladder symptoms

Women with mixed incontinence, a combination of overactive bladder and stress incontinence, reported a greater treatment benefit for overactive bladder symptoms from DETROL® LA (tolterodine tartrate extended release capsules) than placebo, according to new study results published in the August issue of Urology.

21 Aug 2004

Current information on the use of antidepressants in pediatric patients

The Food and Drug Administration has issued an update to provide health care providers and patients with the most current information on the use of antidepressants in pediatric patients.

21 Aug 2004

Authors redefine aging as any change in an organism over time

Voyager Pharmaceutical have announced the publication of a paper co-authored by its chief scientist, Richard Bowen, M.D., and Craig Atwood, Ph.D., research director of the University of Wisconsin Memory Research Program and the Wisconsin Alzheimer's Institute.

18 Aug 2004

New guidelines urge early and long-term treatment with Aldosterone blockade therapy

Patients who have had a recent heart attack with ST-elevation (ST-Elevation Myocardial Infarction, or STEMI), complicated by heart failure should be treated with aldosterone blockers according to new guidelines issued recently by the American College of Cardiology (ACC) and the American Heart Association (AHA).

17 Aug 2004

Nasal cream effective in reducing the symptoms of allergic rhinitis

A nasal cream applied to the inside of the nose appears effective in reducing the symptoms of allergic rhinitis, according to an article in the August issue of The Archives of Otolaryngology – Head & Neck Surgery.

16 Aug 2004

Concern over media coverage surrounding the Tronado microwave treatment of cancer

The Australian Medical Association (WA) today expressed concern over media coverage surrounding the Tronado microwave treatment of cancer.

13 Aug 2004

New biotech alliance to focus on diseases of nerve injury and pain

NeuroTargets Ltd, a discovery-led biotechnology company ‘spun-out’ from the University of Bristol, has formed an exciting new alliance with BioFocus plc, a world leader in collaborative drug discovery, to focus on diseases of nerve injury and pain.

11 Aug 2004

Clinical trial of lipase inhibitor for the treatment of obesity

Peptimmune, Inc. a privately held biotechnology company, announced that physicians have treated the first participant in a clinical trial to evaluate the safety, tolerability and pharmacokinetics of GT389-255, a lipase inhibitor conjugated to a fat binding polymer for the treatment of obesity.

9 Aug 2004

Bush administration is depriving millions access to life-saving generic drugs

AIDS Healthcare Foundation, has commended the World Health Organization (WHO) for their leadership and sincere interest in ensuring the safety of generic HIV/AIDS drugs in the developing world.

6 Aug 2004

Approval of Cymbalta for treatment of major depressive disorder

The U.S. Food and Drug Administration has approved Cymbalta® (duloxetine HCl; pronounced SIM-BALL-TA), judging it a safe and effective treatment for major depressive disorder, Eli Lilly and Company have announced.

5 Aug 2004

Experimental vaccine against ricin

Scientists have developed an experimental vaccine against ricin, a potential biological threat agent, which fully protected mice from aerosol challenge with lethal doses of the toxin.

5 Aug 2004

Atherosclerosis at menopause slowed by diet and exercise

Thickening of artery walls accelerates as women enter menopause, but these signs of the progression of atherosclerosis can be slowed by a lower-fat diet and increased physical activity, according to a new study in the Aug. 4, 2004, issue of the Journal of the American College of Cardiology.

5 Aug 2004

Half of the complications and deaths due to in-hospital DVT can be prevented with once daily dalteparin

Current research supports the use of blood-thinners to help acutely ill, hospitalized patients minimize the risk of death from a pulmonary embolism (PE) and its precursor deep vein thrombosis (DVT).

3 Aug 2004

CV Therapeutics initiates approval-enabling trial of drug to treat chronic angina

CV Therapeutics has announced that it has initiated an approval-enabling study of Ranexa, which, if successful, could support approval of Ranexa for the treatment of chronic angina in a restricted patient population.

3 Aug 2004

Metabasis Therapeutics announces multi-center Phase 2 study to evaluate the orally administered antiviral compound remofovir mesylate

Metabasis Therapeutics has announced the initiation of a multi-center, multi- national Phase 2 study to evaluate the orally administered antiviral compound remofovir mesylate in chronic hepatitis B (HBV) infected patients.

3 Aug 2004

One-third of U.S. adults use some form of alternative medicine

More than one-third of U.S. adults use some form of alternative medicine such as herbal supplements and other therapies, showed in a nationwide survey by NIH's National Center for Complementary and Alternative Medicine published in May 2004.

2 Aug 2004

Efficacy News and Research

Artificial heart can keep patients awaiting heart transplant alive

Powerful new cancer-fighting property of Herceptin

Pfizer receives approval for acute bipolar mania drug

New database about a group of genes associated with multidrug resistance in cancerous tumors

Pfizer drug effectively treats overactive bladder symptoms

Current information on the use of antidepressants in pediatric patients

Authors redefine aging as any change in an organism over time

New guidelines urge early and long-term treatment with Aldosterone blockade therapy

Nasal cream effective in reducing the symptoms of allergic rhinitis

Concern over media coverage surrounding the Tronado microwave treatment of cancer

New biotech alliance to focus on diseases of nerve injury and pain

Clinical trial of lipase inhibitor for the treatment of obesity

Bush administration is depriving millions access to life-saving generic drugs

Approval of Cymbalta for treatment of major depressive disorder

Experimental vaccine against ricin

Atherosclerosis at menopause slowed by diet and exercise

Half of the complications and deaths due to in-hospital DVT can be prevented with once daily dalteparin

CV Therapeutics initiates approval-enabling trial of drug to treat chronic angina

Metabasis Therapeutics announces multi-center Phase 2 study to evaluate the orally administered antiviral compound remofovir mesylate

One-third of U.S. adults use some form of alternative medicine

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest News